January 1999
Volume 40, Issue 1
Free
Articles  |   January 1999
Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis.
Author Affiliations
  • N Kitaichi
    Department of Ophthalmology, School of Medicine, Hokkaido University, Sapporo, Japan.
  • S Kotake
    Department of Ophthalmology, School of Medicine, Hokkaido University, Sapporo, Japan.
  • Y Sasamoto
    Department of Ophthalmology, School of Medicine, Hokkaido University, Sapporo, Japan.
  • K Namba
    Department of Ophthalmology, School of Medicine, Hokkaido University, Sapporo, Japan.
  • A Matsuda
    Department of Ophthalmology, School of Medicine, Hokkaido University, Sapporo, Japan.
  • K Ogasawara
    Department of Ophthalmology, School of Medicine, Hokkaido University, Sapporo, Japan.
  • K Onoé
    Department of Ophthalmology, School of Medicine, Hokkaido University, Sapporo, Japan.
  • H Matsuda
    Department of Ophthalmology, School of Medicine, Hokkaido University, Sapporo, Japan.
  • J Nishihira
    Department of Ophthalmology, School of Medicine, Hokkaido University, Sapporo, Japan.
Investigative Ophthalmology & Visual Science January 1999, Vol.40, 247-250. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N Kitaichi, S Kotake, Y Sasamoto, K Namba, A Matsuda, K Ogasawara, K Onoé, H Matsuda, J Nishihira; Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis.. Invest. Ophthalmol. Vis. Sci. 1999;40(1):247-250.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: To investigate pathogenesis underlying endogenous uveitis, macrophage migration inhibitory factor (MIF) was quantified in sera of patients. METHODS: Sera were obtained from the 55 patients with uveitis (24 with Behçet's disease; 9 with Vogt-Koyanagi-Harada's [VKH] disease; 22 with sarcoidosis) and 58 healthy control subjects. MIF levels were determined by a human MIF enzyme-linked immunosorbent assay. RESULTS: The mean MIF levels in the sera of the patients with Behçet's disease, VKH disease, and sarcoidosis and of healthy control subjects were 60.4+/-9.0 (mean+/-SE) ng/ml, 16.5+/-2.9 ng/ml, 27.1+/-5.6 ng/ml, and 5.4+/-0.04 ng/ml, respectively. The average levels of MIF in the sera of uveitis patients were significantly higher (P < 0.0001) than those of healthy control subjects. The high levels of MIF were especially noted in patients with Behçet's disease at the ocular exacerbation stage and patients with sarcoidosis at the severe uveitis stage. CONCLUSIONS: Significant increase of MIF in sera was characteristic of uveitis, and MIF may be a usefull laboratory parameter to use to comprehend the clinical course of uveitis.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×